ITCI - Intra-Cellular Therapies, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Intra-Cellular Therapies, Inc.

430 East 29th Street
Suite 900
New York, NY 10016
United States

Full Time Employees73

Key Executives

NameTitlePayExercisedYear Born
Dr. Sharon MatesCo-Founder, Chairman, CEO & Pres1.33M692k1953
Mr. Lawrence J. Hineline CPASr. VP of Fin., CFO, Treasurer and Assistant Sec.645.39kN/A1956
Dr. Robert E. DavisSr. VP & Chief Scientific Officer646.12kN/A1951
Mr. Michael I. Halstead J.D.Exec. VP, Gen. Counsel & Sec.710.78kN/A1973
Dr. Kimberly E. VanoverSr. VP of Early Stage Clinical Devel. & Translational Medicine625.18kN/A1966
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Intra-Cellular Therapies, Inc., a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative disorders. The company is developing its lead drug candidate, lumateperone for the treatment of schizophrenia, bipolar disorder, behavioral disturbances associated with dementia, autism, and other CNS diseases. It is also developing ITI-002 that inhibits the enzyme phosphodiesterase type 1; ITI-214 for Parkinson's disease; and ITI-333, for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. is headquartered in New York, New York.

Corporate Governance

Intra-Cellular Therapies, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 7. The pillar scores are Audit: 1; Board: 2; Shareholder Rights: 7; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.